Try GOLD - Free

AI: One earth, one regulatory ecosystem

Business Standard

|

October 24, 2024

Artificial Intelligence (AI) technologies, built on predictive and deterministic analysis of large data sets and patterns, transcend geographies.

- PALLAVI BAJAJ

AI is inherently collaborative, inclusive, agile, and continuously evolving. Naturally, regulation of AI would need to be, too. Regulatory sandboxes cannot cater to ensuring that the inter-connected, fast-evolving AI benefits all, with minimal risks, globally. Cooperation is essential.

India, with 1.4 billion people, and exponentially increasing digital adoption, will play a key role in this discussion. The benefits of AI extend across domainseconomic, social, health, logistics, education, security, and environment. Evidently, the pace and manner of its adoption into everyday activities is unprecedented. A significant dampener to this adoption is inadequate regulation, encouraging misuse, and impacting user confidence. Risks to security-human, national, economic, social-posed by unregulated advancement and accessibility of AI, are evolving with technology, impacting all stakeholders.

Stakeholders make data - the spine of AI. The larger, more diverse, more inclusive the dataset, the lesser the opportunity for unintended bias, more accurate the assessment and outcome. This makes AI assessment inherently collaborative, inclusive, and cross-jurisdictional, with user confidence critical to its enhancement, and associated risks ubiquitous. The need for collaborative regulation to minimise risks while optimising uptake and enhancement follows naturally.

The current global scenario where AI regulation is fragmented in individualistic sandboxes is sub-optimal.

The race for regulatory "leadership" is counter-intuitive.

There cannot be a legitimate first-mover advantage when effective regulation naturally necessitates cross-jurisdictional collaboration.

MORE STORIES FROM Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size